Akeso's valuation has somewhat priced in the success of AK112’s head-to-head trial with KEYTRUDA.But if AK112 fails in critical trials, it will cast a shadow on the entire bispecific antibody pipeline
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.